A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration

• Status: Active, not recruiting
• Trial end date: 2029-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the long term safety of an experimental gene transfer agent, RetinoStat®, designed to treat neovascular age-related macular degeneration.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oxford BioMedica

Criteria

Inclusion Criteria:

• Must have received a subretinal injection of RetinoStat

• Must have been enrolled in Protocol RS1/001/10

Exclusion Criteria:

• Did not receive RetinoStat® as part of the RS1/001/10 protocol